Correlation of telomere length with biologic and clinical factors. (A) Telomere length distribution in MCL and CLL samples with mutated/unmutated IGHV and mutant/wild-type TP53 and in normal B cells from healthy donors. (B) Correlation of telomere length with proliferation index (Ki67) levels. (C) Telomere length distribution among MCL lymph node samples with and without different genomic aberrations such as del(9p21), del(11q22-q23), del(13q14), del(13qTerminal), and del(17p13). (D) Telomere length distribution among MCL peripheral blood samples with and without different genomic aberrations such as del(9p21), del(11q22-q23), del(13q14), del(13qTerminal), and del(17p13). (E) Telomere length variation with the number of genomic aberrations detected using FISH and/or array-CGH (2 outliers with 0 and 1 genomic aberration detected were removed). (F) Relation of telomere lengths to clinical features in MCL samples. (G) Overall survival in the short (< median) and long telomere (> median) subgroups (median, 48 months; P = .8174). (H) Progression-free survival in the short (< median) and long telomere (> median) subgroups (median 25 vs 22 months; P = .8644). The lines in panels A, C, D, and F represent the median.